# Safety of Ibritumomab Tiuxetan (Zevalin®) in Combination With a Fludarabine-based Reduced Intensity Conditioning (RIC) Regimen (ZEVALLO 2007)

> **NCT00607854** · PHASE2 · COMPLETED · sponsor: **University Hospital, Bordeaux** · enrollment: 31 (actual)

## Conditions studied

- Diffuse Large B-Cell Lymphoma
- Mantle Cell Lymphoma

## Interventions

- **DRUG:** Ibritumomab Tiuxetan (Zevalin)

## Key facts

- **NCT ID:** NCT00607854
- **Lead sponsor:** University Hospital, Bordeaux
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-02
- **Primary completion:** 2011-02
- **Final completion:** 2011-11
- **Target enrollment:** 31 (ACTUAL)
- **Last updated:** 2016-10-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00607854

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00607854, "Safety of Ibritumomab Tiuxetan (Zevalin®) in Combination With a Fludarabine-based Reduced Intensity Conditioning (RIC) Regimen (ZEVALLO 2007)". Retrieved via AI Analytics 2026-07-30 from https://api.ai-analytics.org/clinical/NCT00607854. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*